Persistence of the anal fissure · patients with fissure in ano
Open showed no clear difference in persistence of the anal fissure compared with closed partial lateral internal sphincterotomy (high certainty).
1 finding from 1 review
Minor incontinence to flatus · patients with fissure in ano
Open showed no clear difference in minor incontinence to flatus compared with closed partial lateral internal sphincterotomy (moderate certainty).
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (no data) · schizophrenia
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with zuclopenthixol depot (very low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in adverse effects: 1. Extrapyramidal side effects (TESS) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Sedation/tranquillisation: Not sedated ‐ at four hours · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Global state: 1. Requiring supplementary medication ‐ antipsychotics · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Mental state: 1. Not markedly improved (BPRS, < 60% decrease in BPRS score) · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in mental state: 1. Not markedly improved (BPRS, < 60% decrease in BPRS… compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (no data) · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride (Cis Z isomer) changes adverse effects: Clinically important general adverse effect compared with zuclopenthixol (Cis Z/Trans E isomer) (very low certainty).
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review